Aeschbacher, Marc
Lade...
E-Mail-Adresse
Geburtsdatum
Projekt
Organisationseinheiten
Berufsbeschreibung
Nachname
Aeschbacher
Vorname
Marc
Name
Aeschbacher, Marc
36 Ergebnisse
Suchergebnisse
Gerade angezeigt 1 - 10 von 36
Publikation A concept for team development and team optimisation(2024) Aeschbacher, Marc; Legena, Valeria; Smuts, Hanlie; Hinkelmann, Knut04B - Beitrag KonferenzschriftPublikation Leading in society 5.0, The 5Co leadership concept(2023) Aeschbacher, Marc; Legena, Valeria; Gerber, Aurona; Hinkelmann, Knut04B - Beitrag KonferenzschriftPublikation Mentaltraining als Selfmanagementpraxis im Beruf(Schäffer-Poeschel, 2021) Aeschbacher, Marc; Legena, Valeria; Schulte, Volker; Steinebach, Christoph; Veth, Klaske04A - Beitrag SammelbandPublikation Case Study «Amunemi»(edition gesowip, 2020) Aeschbacher, Marc; Verkuil, Arie Hans; Meyer, Rolf; Aeschbacher, Marc04A - Beitrag SammelbandPublikation Case Study «Derma2go»(edition gesowip, 2020) Eisenbart, Barbara; Verkuil, Arie Hans; Meyer, Rolf; Aeschbacher, Marc04A - Beitrag SammelbandPublikation Start-ups. Aktuelle Case Studies für den Unterricht(edition gesowip, 2020) Verkuil, Arie Hans; Meyer, Rolf; Aeschbacher, Marc03 - SammelbandPublikation Case Study «Bureau Futur»(edition gesowip, 2020) Schulte, Volker; Verkuil, Arie Hans; Meyer, Rolf; Aeschbacher, Marc04A - Beitrag SammelbandPublikation Case Study "Perseo Pharma"(edition gesowip, 2020) Kabous, Laila; Verkuil, Arie Hans; Meyer, Rolf; Aeschbacher, MarcFounded in 2019, Perseo Pharma is a preclinical-stage biotech company with a unique asset for the development of enzyme therapies. Perseo Pharma possesses an innovative and proprietary enzyme shielding technology. Founded as independent spin-off of INOFEA AG, the company focuses on therapeutic enzymes for the treatment of cancer and rare genetic diseases. Over the past three decades, 30 therapeutic enzymes have been approved by EMA and FDA generating yearly 40bn. Therapeutic enzymes address a wide variety of indications, ranging from rare genetic diseases (enzyme replacement therapies) to oncology (key tumor-element depletion therapies). This offers biotech companies different opportunities and application fields for further development of enzyme therapeutics. The goal of this research is to analyze the case based on the 7-key model and provide recommendations on the financing opportunities available for Perseo pharma.04A - Beitrag SammelbandPublikation Case study essento(edition gesowip, 2020) Meyer, Rolf; Verkuil, Arie Hans; Aeschbacher, Marc04A - Beitrag SammelbandPublikation Digital ecosystem. How companies can achieve a sustainable competitiveness in the future and the digital age(edition gesowip, 2019) Grieder, Hermann; Schwaferts, Dino; Verkuil, Arie Hans; Hinkelmann, Knut; Aeschbacher, MarcCompanies today are still highly influenced by the management theories of the indus-trial age. To be successful in the future companies need to become part of digital eco-systems where partners and customers will be co-creators. Customers and employees’ expectations are changing, and managers need to re-evaluate traditional management methods to enable companies to successfully transition into the digital era. During the transition, we will see a change from sociotechnical systems to transitional constructs that enable co-creation and collaboration. Digital Arenas will allow companies to create value outside of their industry by collaborating with other companies through APIs; this will give rise to new business models everywhere.04A - Beitrag Sammelband